| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3328115 | Acta Haematologica Polonica | 2015 | 7 Pages |
Abstract
Relapsed and refractory acute myeloid leukemia (AML) is defined by clinical and biologic features that predict their poor response to therapy. Despite even the most aggressive and well-developed strategies for treatment, most patients succumb to the disease. No currently available treatment has demonstrated consistent efficacy in terms of salvage therapy or long-term survival in this group of patients. This review will discuss some of the emerging strategies: targeted molecular therapies, novel cytotoxics, and immune-based therapies to treat relapsed and refractory AML patients.
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
Beata Piątkowska-Jakubas, Agnieszka Sporek-Kunicka,